NEUROENDOCRINE CARCINOMA OF PROSTATE

This adverse event was reported 16 times

These drugs are most commonly taken by patients reporting NEUROENDOCRINE CARCINOMA OF PROSTATE:

# Drug Count
0 DOCETAXEL 3
1 DOCETAXEL ANHYDROUS 3
2 LEUPROLIDE ACETATE 3
3 CARBOPLATIN 2
4 ENZALUTAMIDE 2
5 ABIRATERONE ACETATE 1
6 ALISKIREN 1
7 ALISKIREN HEMIFUMARATE 1
8 AMLODIPINE 1
9 BICALUTAMIDE 1
See all common drugs associated with NEUROENDOCRINE CARCINOMA OF PROSTATE

NEUROENDOCRINE CARCINOMA OF PROSTATE is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LAROTRECTINIB 1 0.0030
1 CABAZITAXEL 1 0.0004
2 ALISKIREN HEMIFUMARATE 1 0.0002
3 CLONIDINE HYDROCHLORIDE 1 0.0002
4 TERAZOSIN HYDROCHLORIDE 1 0.0001
5 LABETALOL 1 0.0001
6 EVEROLIMUS TABLETS 1 0.0001
7 BICALUTAMIDE 1 0.0001
8 LEUPROLIDE ACETATE 3 0.0001
9 DOCETAXEL ANHYDROUS 3 0.0001
See all drugs enriched for association with NEUROENDOCRINE CARCINOMA OF PROSTATE

NEUROENDOCRINE CARCINOMA OF PROSTATE is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Androgen Receptor Inhibitor [EPC] 3 0.0001
1 Microtubule Inhibitor [EPC] 4 0.0000
2 Topoisomerase Inhibitor [EPC] 1 0.0000
3 Platinum-based Drug [EPC] 3 0.0000
4 Interleukin-12 Antagonist [EPC] 1 0.0000
5 Interleukin-23 Antagonist [EPC] 1 0.0000
6 Aldosterone Antagonist [EPC] 1 0.0000
7 alpha-Adrenergic Blocker [EPC] 1 0.0000
8 Osmotic Laxative [EPC] 1 0.0000
9 Kinase Inhibitor [EPC] 2 0.0000
See all drug classes enriched for association with NEUROENDOCRINE CARCINOMA OF PROSTATE